No Data
Alt: 2024 third quarter Earnings Conference materials
Alt: Summary of financial results for the 3rd quarter of the fiscal year ending 2024/12 [Japanese GAAP] (unconsolidated)
Asahi, Matsukiyo, Dentsu Group, Lancers (14th) (1379-4990)
※The above calendar is merely a schedule and may be subject to change due to the company's circumstances. --------------------------------------- November 14 (Thursday) <1379> Hokuto <1380> Akikawa Bokuen <142A> Jinjibu <1438> Gifu Landscape <1443> Giken HD <1446> Candiule <1447> SAAF HD <145A> El
Individual investor, Yugetsu Yugen: Hoping for a bright market after the lower house election, focusing on performance expectations and speculative stocks. [FISCO Social Reporter]
The following is a comment written by a personal investor, Mr. Yugen Tei, a FISCO Social Reporter (Blog: Profitable Stock Information "The Cat's Master's Stocks Do Not Know the Ceiling").
The Tokyo Stock Exchange Growth Market Index saw a sharp rebound, turning around to show strong movements throughout the day.
Tokyo Stock Exchange Growth Market Index 781.70 +24.55 / Volume 0.1 billion 98.45 million shares / Trading value 85 billion yen Tokyo Stock Exchange Growth Market 250 Index 609.88 +20.58 / Volume 73.44 million shares / Trading value 56.2 billion yen In today's growth market, both the Tokyo Stock Exchange Growth Market Index and the Tokyo Stock Exchange Growth Market 250 Index rebounded significantly. The number of advancing issues is 480, declining issues 83, unchanged 25. In the 25th day's market in the USA, the Dow Jones Industrial Average fell by 259.96 dollars to 42,114.
Emerging Markets Stock Digest: ULTZ fell sharply, while Yumetenbo hit the daily limit.
<4579> Rakoria Pharmaceuticals fell for the 10th consecutive time to 465. Rakoria Pharmaceuticals announced that through South Korea's HK InoEn, it licensed the gastric acid secretion inhibitor "tegoprazan", which China's Luoxin obtained sales approval from the National Medical Products Administration for combination therapy for Helicobacter pylori (H. pylori) infection. Rakoria Pharmaceuticals will not receive any one-time payment for this matter, but the approval in China is for the medium to long term.
No Data
No Data